PMOS: International Naming Change for PCOS Aims to Reduce Stigma and Improve Diagnosis

Overview

Science Quickly hosts Anuja Dokris to discuss Polyandocrine Metabolic Ovarian Syndrome PMOS, the proposed new name for polycystic ovary syndrome, and the international collaboration shaping its adoption. The conversation covers origins, the inclusive process that involved patients, and the anticipated benefits for diagnosis and research.

Key insights

• International, patient-centered renaming effort spanning over a decade and thousands of surveys
• Move toward a scientifically accurate, stigma-reducing acronym that remains easy to use
• Delphi-style consensus with dozens of medical societies and patient groups guiding the change
• Expected improvements in early diagnosis, broader clinician awareness, and expanded research funding

Introduction: A naming issue rooted in history and stigma

The podcast centers on the renaming of polycystic ovary syndrome to Polyandocrine Metabolic Ovarian Syndrome PMOS. The guest, Anuja Dokris, explains that the rebrand emerged from a long international collaboration among clinicians, researchers, patients, and even marketing consultants. The core motivation is to correct decades of inaccuracies associated with the term, notably the misconception that the condition involves ovarian cysts. The discussion situates the naming effort within a broader push to recognize the metabolic, cardiovascular, dermatological, and psychological dimensions of the syndrome, and to reduce the stigma surrounding infertility that often accompanies the term “ovary syndrome.” Dokris holds leadership roles at the Penn PMOS center and the University of Pennsylvania, underscoring the strong academic backing for the initiative.

Origins: From a 2012 NIH meeting to a 2026 rebrand

The naming effort traces back to 2012, when a National Institutes of Health (NIH) meeting brought together a multidisciplinary group to review PCOS. A white paper followed, recommending discussion of a name change due to new research and the absence of cysts in many patients by 2015. Later, when Dokris served as president of the Androgen Excess PCOS Society, a session invited patients for the first time to discuss the name change. At that session, the field recognized that a premature shift would be risky given gaps in diagnosis, diagnostic criteria, and management. A key turning point was a broader, international effort to create guidance for diagnosis, assessment, and management, culminating in the first international PCOS guidelines and subsequent updates, including a 2023 revision. The final push toward the 2026 new name came after renewed surveys of patients and clinicians who weighed the pros and cons of different naming options and acronyms. The process was designed to ensure scientific accuracy, non-stigmatizing language, cultural appropriateness, and ease of use for both patients and clinicians.

Missed opportunities in education and diagnosis

The transcript highlights several gaps: the word polycystic has persisted for decades despite ultrasound evidence that patients often present without cysts. This mischaracterization contributes to misinformation and anxiety in patients and can misdirect clinical conversations. The panel also notes that the condition is not purely gynecologic; irregular menses, dermatological symptoms, hirsutism, acne, and weight issues intersect with cardiovascular risk, metabolic syndrome, and mental health concerns. These realities demanded a more comprehensive naming framework to reflect the full spectrum of associated risks and to promote a broader, more integrated approach to screening and management.

The naming process: an inclusive, data-driven approach

What followed was an inclusive process that involved patients from the outset and built on a framework established during guideline development. The team weighed options such as whether to emphasize reproduction or ovarian pathology while considering the stability of the acronym PCOS. The majority preference favored a name that was scientifically accurate, non-stigmatizing, culturally adaptable, and easy to remember. Marketing input cautioned against a drastic change that would confuse patients and providers, suggesting instead a subtle but meaningful shift. The final decision retained the term ovarian syndrome in the name while introducing a descriptor that better captures the metabolic and endocrine complexities of the syndrome.

Delphi consensus: evidence-driven, global buy-in

The consensus process described in the podcast is a structured Delphi method, a rigorous, multi-round surveying approach used to synthesize expert opinions. The process included approximately 90 stakeholders across patients and clinicians from endocrinology, pediatrics, gynecology, primary care, and other specialties, plus representatives from about 50 medical societies and 38 professional organizations. This extensive, transparent process allowed for multiple rounds of virtual meetings and discussions until a final steering group reached broad agreement. The Delphi method ensured that both patient experiences and clinical knowledge were reflected in the final naming decision. Dokris notes that this was one of the largest multi-stakeholder efforts in medicine, akin to other substantial name changes in medical history, but with its own unique breadth and depth.

Reception, challenges, and implementation

Public reaction to the publicizing of the name change has been largely positive, with social media conversations highlighting that the rebrand is overdue and that a single letter change can carry significant meaning in perception and diagnosis. Nevertheless, there was pushback about whether the change occurred too quickly or would cause confusion during transition. The interviewees acknowledge that institutions and patient organizations that currently embed the PCOS acronym will require time and resources to rebrand. There are logistical questions about translating existing research, guidelines, and patient records into the PMOS framework, and about ensuring that ongoing studies and datasets remain compatible with the new terminology. Dokris emphasizes that this renaming is not a cancellation of prior work but a rebranding that can unlock new lines of inquiry and collaboration across fields such as cardiology, endocrinology, dermatology, and mental health, potentially widening funding streams for women's health research.

Expected impact: patient care, education, and research funding

From a patient perspective, PMOS is expected to reduce confusion and stigma by shifting emphasis away from cysts toward a broader understanding of metabolic and hormonal factors. The new name also invites earlier and more holistic conversations with general practitioners and adolescent medicine specialists, given that the condition often presents in adolescence and intersects with everyday health management. For clinicians, the PMOS framework can streamline diagnostic workups and promote consistent criteria across regions, reducing variability in care. Dokris highlights the potential for renewed interest from institutions that fund cardiovascular and endocrine health to invest more in PMOS-related research, which could lead to more comprehensive, cross-disciplinary treatment approaches and improved patient outcomes. The Penn PMOS center’s leadership signals a sustained commitment to advancing this integrated approach within clinical care and research programs.

Looking ahead: the future of PMOS in medicine

The podcast ends with a forward-looking note on the broader implications of the renaming: improved awareness across medical specialties, earlier diagnosis, and better alignment of research funding with real-world patient needs. The name PMOS is framed as a symbol of a more accurate and inclusive understanding of the syndrome, with a focus on metabolic and endocrine dimensions, cardiovascular risk, mental health, and the lived experiences of patients. The speakers stress that the work is ongoing and that implementation will require continued collaboration among clinicians, patients, and research institutions worldwide. The renaming is presented as a major milestone that could transform both clinical practice and research funding over time, while remaining mindful of the need to support the many clinicians and patients who have built knowledge under the PCOS framework.

Conclusion: a measured step toward better health outcomes

The podcast frames PMOS as a carefully considered, evidence-based update designed to improve diagnostic accuracy, reduce stigma, and broaden research opportunities. While the name change is not a panacea, it represents a significant alignment of language with contemporary scientific understanding and patient-centered care. The episode underscores that the path from naming to widespread clinical and research adoption involves ongoing communication, education, and collaboration across medical disciplines and patient communities, with the ultimate aim of improving health outcomes for people affected by polycystic ovary syndrome and related metabolic ovarian conditions.